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Abstract 
Phospholemman (PLM) is a regulatory subunit of the cardiac Na+/K+-ATPase (NKA), 
but exists also as an independent tetramer. The membrane spanning protein consists 
of 72 amino acid residues and is the first member of the FXYD motif-containing 
family of tissue specific NKA regulatory subunits (FXYD1). A comparative model of 
the human PLM/NKA complex shows the interactions between NKA and the 
extracellular FXYD motif as well as the transmembrane helix-helix interactions. A 
variety of intracellular posttranslational modifications points to a highly dynamic 
picture of interactions between NKA and the intracellular part of PLM. 
Posttranslational modifications of PLM include NKA-activating phosphorylation, 
inhibiting palmitoylation and activating glutathionylation. PLM gene expression has 
the potential for posttranscriptional regulation by the formation of potassium-ion 
stabilised G-quadruplex structures in pre-splicing mRNA. The overall physiological 
role of cardiac PLM is to protect the heart under conditions of increased heart rate 
and oxidative stress avoiding calcium overload of the cytoplasm and arrhythmias. 
The PLM tetramer possibly exists as a storage pool in order for the heart to react 
quickly to changing conditions. 
Key words: fxyd1, cardiac protein, transmembrane protein, protein-protein 
interactions, posttranslational modification, oligomerisation 
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1 Introduction 
The Na+/K+-ATPase (NKA) is a P-type ATPase originally discovered by Skou [1] and 
responsible for the export of three sodium ions to the outside of the cell and the 
import of two potassium ions. This ion transport against the concentration gradient 
is driven by the hydrolysis of ATP. The ion gradient established by NKA is essential 
to many membrane transport processes including the generation of action potentials 
in nerve and muscle cells. NKA is composed of a minimum of two subunits, namely 
the catalytically active α subunit with a molecular mass of approximately 100 kDa 
and the β subunit with approximately 33 kDa (in humans), which is required for 
intracellular transport of NKA to the plasma membrane [2]. At least four isoforms of 
α subunits and three β isoforms are known, while in cardiac muscle α1β1 and α2β1 are 
mainly expressed. With ouabain-based photoaffinity labels a third γ subunit (also 
known as FXYD2) was discovered in the porcine kidney [3] and later it was reported 
that NKA is generally associated with a third subunit. Whether this association is 
permanent or transient remains a matter of investigation. The identity of the third 
subunit varies in different tissues, but the FXYD (phenylalanine-X-tyrosine-aspartate) 
sequence motif is common to the third subunit in all tissues [4]. In cardiac muscle 
tissue the third subunit is termed phospholemman [5] or FXYD1, which is also used 
as the name of the gene encoding for the protein phospholemman (PLM).  
While the structure and function of NKA has been reviewed in chapter 1 of this 
volume, this chapter focuses on the structural and biochemical aspects of the NKA 
regulation by PLM and its physiological consequences. First, the protein structure of 
PLM is discussed with reference to various sites of posttranslational modification, 
followed by the structure of the human FXYD1 gene and its potential for regulation 
at the level of transcription and mRNA processing, and finally the physiological 
consequences of PLM-NKA interaction are reviewed. Many excellent reviews about 
PLM and its physiological role in particular have appeared in the literature [6-9] and 
should be consulted by the interested reader in addition to the present chapter.   
 
2 Phospholemman sequence and structure 
The protein phospholemman (PLM) was originally characterised as a major plasma 
membrane substrate of protein kinase A (PKA) and C (PKC) that consisted of 72 
amino acid residues in the mature protein and a cleavable 20-residue N-terminal 
signal sequence [10]. PLM is expressed in the canine heart, skeletal muscle, smooth 
muscle and liver, while it is absent from the brain and the kidney. Later, as outlined 
above, PLM was classified as the first member of the FXYD class of proteins [4]. The 
phosphorylation sites have been identified in later studies as Ser63 (PKC) and Ser68 
(PKA and PKC) and Thr69 (PKC) [11]. Palmitoylation occurs at Cys40 and Cys42 [12] 
and glutathionylation at Cys42 [13].  Due to the increasing number of genome 
sequencing projects we can, at the time of writing, identify 25 sequences of FXYD1 
from UniProt [14]. Except the Ophiophagus hannah (King cobra) FXYD1, all other 24 
organisms FXYD1 sequence show >50% sequence identity. The multiple sequence 
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alignment of FXYD1 protein sequences without signal sequence is shown in figure 1 
colour coded by conservation with a blue-red gradient. It can be seen that there are 
very few variations to the FXYD motif. Other regions of high conservation are the 
transmembrane domain as well as the intracellular C-terminal domain between 
Cys40 and Arg66 with some exceptions. Note that PLM follows the positive-inside 
rule for transmembrane proteins [15] showing a higher number of positively charged 
residues on the intracellular part of the protein as well as aromatic residues Tyr11 
and Tyr13 at the membrane water interface. 
2.1 The phospholemman monomer 
The 3D-structure of the PLM monomer was determined by solution-state NMR  
spectroscopy (PDB-ID: 2JO1) in SDS micelles at pH 5 [16]. It reveals, in addition to a 
long helix from Gln14 to Phe44 encompassing the transmembrane domain, short 
helical segments in the N-terminal part and a longer helical segment from Phe60 to 
Thr69 in the C-terminal part.  The angle of the helical axes between the two main 
helical segments is approximately 90° giving rise to the characteristic L-shape of the 
PLM monomer.  The C-terminal part including the helix is very basic containing 
altogether six Arg residues between Phe60 and Arg72, thus it is positively charged at 
physiological pH. This explained the association with the negatively charged micelle 
surface in the NMR study. Teriete et al. suggested that negative charges introduced 
by phosphorylation could lead to a reorientation of the C-terminal segment 
facilitated by the flexible linker region between Asp45 and Thr59. Interestingly there 
is a high level of conservation in the linker region among FXYD1 orthologues (fig. 1). 
2.2 The phospholemman tetramer 
Gel-electrophoresis of synthetic PLM transmembrane peptides with perfluoro-
octaneoate, a detergent that keeps transmembrane protein complexes intact, has 
shown that PLM forms tetramers [17]. In the same study it was shown by attenuated 
total reflection Fourier transform infrared spectroscopy (ATR-FTIR) that the lipid-
membrane embedded tetramers are α-helical and have a predominantly 
transmembrane orientation similar to the monomer structure obtained in SDS 
micelles.  A solid state magic angle spinning 17O-NMR study of the lipid-membrane 
embedded PLM transmembrane domain indicated that the tetramer is not 
completely symmetric, but may have a C2 (dimer of dimers) or C1 rotational 
symmetry along the bilayer normal [18]. An atomic structural model of the 
tetrameric PLM transmembrane domain was obtained by a combination of 
orientational constraints derived from site-specific infrared dichroism [reviewed in 
19] and a systematic conformational search based on molecular dynamics simulation 
of a transmembrane helical bundle protein [20]. The PLM transmembrane helical 
bundle reveals an average helix tilt angle of 7.3° in line with the previous solution 
state NMR-study of the monomer. The tetramer is closely packed and does not show 
any indication of an open pore in the centre of the tetramer. However, the helix-helix 
packing shows the unusual feature that some small residues, such as Gly19 and 
Gly20, point to the outside of the helical bundle (figure 2a), which supported the 
hypothesis that a PLM tetramer may occur in vivo as a storage form that readily 
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interacts with NKA [21]. A two-stage model of PLM-NKA interaction was proposed 
that involves a slow interaction of the PLM tetramer with NKA leading to the 
abstraction of one PLM monomer (figure 2b). In the second stage the remaining PLM 
trimer interacts fast with other NKA molecules. The existence of PLM tetramers in 
human embryonic kidney cells has been confirmed by fluorescence resonance energy 
transfer (FRET) and it was shown that the tetramer is stabilised by phosphorylation 
[22]. More recently the existence of PLM homo-oligomers was reported in cardiac 
muscle [23]. In this carefully conducted study a significant proportion of PLM (>50%) 
was identified that was not associated with NKA but formed a separate pool of 
multimeric PLM. The stoichiometry of multimeric PLM was not clearly identified, 
but using formaldehyde crosslinking without denaturation prior to electrophoresis 
resulted in a band consistent with a tetramer that was detected by Western-blotting 
probed with a PLM-phospho-Ser68 specific antibody. The phosphorylation pattern of 
NKA-associated and multimeric PLM is different, with NKA associated PLM being 
unphosphorylated or phosphorylated at Ser68, while multimeric PLM shows Ser63 
phosphorylation in addition to phosphorylation at other sites. It was suggested that 
phosphorylation does not change the distribution between multimeric and NKA-
associated PLM, but the protein phosphatase PP2A associated with NKA leads to a 
dephosphorylation of PLM-Ser63 [23]. The PLM multimer in cardiac muscle cells 
located in the same membrane compartment as NKA does not seem to interact with 
other proteins, thus it was suggested that it acts as storage pool for PLM confirming 
the postulation made in earlier work [21]. There is a potential parallel to 
phospholamban (PLB) that regulates the sarco/endoplasmatic reticulum Ca-ATPase 
(SERCA). Although not related by sequence similarity, PLB is structurally similar to 
PLM with 52-amino acid residues and one transmembrane domain. It associates with 
and regulates SERCA via phosphorylation and exists as a pentamer in its non-
associated form [reviewed in 24]. Since PLB shows measureable ion channel activity, 
the function of the PLB pentamer is still under discussion [25,26], while based on the 
structure of the PLM tetramer transmembrane domain, no potential for ion 
conduction was found [21], thus the hypothesis of the PLM tetramer as a storage 
pool for regulation of NKA seems the most likely one. 
 
2.3 The structure of the phospholemman-NKA complex 
The atomic structure of the cardiac human phospholemman-NKA complex is not 
known, but a number of potassium-bound homologue structures are available in the 
Protein Data Bank, namely the pig renal NKA with parts of FXYD2 at 3.5 Å 
resolution (PDB-ID: 3B8E) [27], a shark NKA model in the E2 state with FXYD10 at 
2.4 Å resolution (PDB-ID: 2ZXE) [28] and a sodium bound form from pig kidney at 
4.2 Å resolution (PDB-ID: 4HQJ) [29]. In particular the high resolution shark NKA 
model shows a large portion of the FXYD10 subunit including the FXYD motif. The 
sequence identity between the shark and the human NKA subunits is 88% for the α-
subunit, 65% for the β-subunit and 35% between FXYD10 and PLM, while a 30% 
sequence identity is considered as the lower limit for comparative modelling [30]. For 
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this review we have prepared a comparative model of the human NKA/PLM 
complex using the shark 2ZXE and the human PLM monomer structure (2JO1, 100% 
sequence identity) as templates with the explicit inclusion of three potassium ions, 
one Mg2+ and one phosphate analogue MgF42- ion found in the 2ZXE template. The 
structure of this comparative model shown in figure 3 is discussed in the following 
text. The PLM backbone structure is coloured according to sequence conservation 
showing a tendency towards lower conservation of residues facing away from NKA. 
The arrangement of subunits is shown in figure 4a, revealing the details of the 
interactions of the FXYD1 motif with NKA (figure 4b), namely Phe9 is interacting 
with residues Val183, Gln69 Val72, Ala73, Phe186 of the β-subunit, and Tyr11 is 
interacting with Tyr68, Asp70 (β-subunit), Lys984, Pro985 (α-subunit), while Asp10 is 
not involved in close interactions with its side chain pointing towards the solvent.  
The palmitoylation sites Cys40 and Cys42 are located at the C-terminal end of the 
long helix and face to opposite sites of the helix. Cys40 points towards the outside 
(fig. 4c), while Cys42 (hidden in fig. 4c) points towards the α-subunit with the closest 
contact being the guanidinium group of Arg353 at a distance of 5.8 Å from the 
cysteine sulphur atom. The positive Arg328 could stabilise the thiolate anion of 
Cys42 at physiological pH, which may explain the susceptibility of Cys42 to 
glutathionylation (see section 4.3). The thiolate anion is much more reactive towards 
forming disulphide bonds than the protonated form. Some information about the 
structural consequences of phosphorylation comes from fluorescence resonance 
energy transfer (FRET) experiments between cyan fluorescent protein labelled NKA 
and yellow fluorescent protein labelled PLM. Upon phosphorylation of Ser63 and 
Ser68, the amount of FRET decreased indicating that the intermolecular distance 
between PLM and NKA was increased [31]. It is possible that phosphorylation 
increases the flexibility of the PLM C-terminus and releases it from NKA binding 
sites. Another possibility is that the phosphorylated PLM C-terminus shifts to other 
phospho-specific NKA binding sites as indicated by experiments with PLM knockout 
mice. Upon addition of a synthetic Ser68 phosphopeptide (PLM residues 54-72), 
NKA activation was observed [32]. A FRET study that investigated alanine 
mutations on the α1-subunit of NKA at Phe956, Glu960, Leu964 and Phe967 
identified the interaction between Glu960 and Phe28 of PLM to be among the critical 
interaction sites between PLM and NKA. The comparative model of NKA/PLM 
developed for this review identifies a close interaction between Glu960 and Phe28 as 
shown in figure 5, although this information was not included in the modelling 
protocol. The structure of the short C-terminal helix containing the phosphorylation 
sites is entirely based on the solution-state NMR structure of the PLM monomer, thus 
the orientation and any interactions shown are not indicative of the native PLM-NKA 
complex. In the absence of structural detail, even available through comparative 
modelling, molecular dynamics simulations of the PLM-NKA complex in realistic 
lipid bilayers [33] could be carried out to assess the molecular details of this 
interaction.    
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3 The phospholemman/FXYD1 gene 
The human FXYD1 gene is located on the q arm of chromosome 19 from bases 
35,138,789 - 35,143,055 (assembly GRCh38) amounting to 4286 bases in the full 
transcript. There are in total eight exons including one 5’ and one 3’ untranslated 
exon. As outlined above the PLM protein is a target of significant posttranslational 
modification. Another way to regulate proteins is via the regulation of gene 
expression. As part of the ENCODE project transcription factors associated with 
genes were identified with ChIP-Seq (Chromatin Immuno-Precipitation Sequencing) 
experiments [34]. Using the ENCODE ChIP-Seq Significance Tool [35] a number of 
potential transcription factors were found around the transcription start site of 
FXYD1 (shown in table 1). Among general transcription factors, such as TAF 
required for the DNA transcription activity, there are a number of transcription 
factors involved in cell differentiation, such as BHLHE40 and EGR1. P300 is the only 
cardiac-related transcription factor implicated in the enlargement of cardiac 
myocytes. This may reflect the variety of cell types analysed in the ENCODE project 
with underrepresentation of cardiac myocytes due to the difficulties of obtaining 
functional cardiac myocytes in cell culture. It can, however, be concluded that the 
FXYD1 gene is under the control of transcription factors. 
The initial pre-mRNA transcript is subjected to the process of splicing and eleven 
transcripts are reported in Ensembl Human Release 77 [36]. Nine of those are 
supported by at least one expressed sequence tag (transcript support level 1 to 3). 
Most transcripts differ in the position of the transcription start site and the length 
and or existence of the last non-protein coding exon. Transcript FXYD1-008 encodes 
for a 115 residue protein that contains a 27 residue insert after the transmembrane 
domain (after LIVLS in figure 1). The 115 residue protein appears to have a 12-
residue shortened signal peptide, but a 5’ truncation in the transcript evidence 
prevented the complete assignment of the coding sequence, thus the transcript may 
indeed contain the full 20-residue signal peptide.  Two of the well supported 
transcripts, FXYD1-004 and FXYD1-010 have a retained intron but do not contain any 
protein coding region as annotated by the HAVANA team [37]. 
A computational analysis of the Homo sapiens FXYD1 pre-mRNA alongside sixteen 
orthologues revealed that the FXYD1 pre-mRNA contains sequences capable of 
folding into higher-order intramolecular RNA structures called G-quadruplexes and 
that this feature is conserved in evolution [38]. G-quadruplexes are formed by square 
planar arrangements of four guanine bases (G-tetrads) stabilised by hydrogen bonds. 
At least two G-tetrads stack together stabilised by sandwiched potassium ions [39]. 
In FXYD1 and orthologues it was found that stretches of three Gs were conserved 
indicating that three G-tetrads could form a stable G-quadruplex structure. Using 
synthetic oligonucleotides with sequences taken from human and bovine FXYD1 pre-
mRNA, the formation of G-quadruplexes was shown in vitro using fluorescence 
spectroscopy and native polyacrylamide gel electrophoresis [38]. It is interesting to 
note in the context of the sodium-potassium exchanging NKA that the required 
potassium ion concentration for stable G-quadruplexes to form is in the region of 100 
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mM, which is similar to the intracellular potassium ion concentration of 120 mM. 
Considering the evolutionary conservation of G-quadruplex forming sequences it 
was suggested that G-quadruplex formation of FXYD1 pre-mRNA may control the 
splicing (either through inhibition or favouring alternative spliced products) and 
thus the expression of the phospholemman protein product [38] (see figure 6). 
However, these in-vitro results await further experimental confirmation in particular 
in cardiomyocytes. 
 
4 Physiology of NKA regulation by phospholemman 
While the presence of PLM is not essential for survival as PLM knockout experiments 
have shown [40], PLM may have a protective role for the heart under conditions such 
as increased heart rate and oxidative stress. PLM knockout mice showed  slightly 
depressed cardiac contractile function as well as a mild cardiac hypertrophy. Under 
the conditions of increased stimulation frequency and β-adrenoreceptor activation 
PLM knockout mice showed a larger increase in intracellular sodium concentration, a 
larger calcium load of the sarcoplasmic reticulum and a larger calcium transient 
leading to more arrhythmias compared to wild type mice [40]. Therefore it was 
postulated that the physiological role of PLM “may be to limit the rise in intracellular 
Na+ during sympathetic stimulation and thereby preventing Ca2+ overload and 
triggered arrhythmias in the heart” [8]. 
 
4.1 Phospholemman phosphorylation and dephosphorylation 
PLM is phosphorylated by protein kinase A (PKA) at Ser68 [41] and at Ser63, Ser68 
and Thr69 by protein kinase C [11]. The biochemical consequences of PKA 
phosphorylation is an increase in sodium affinity [42], while PKC phosphorylation 
increases vmax [43]. Overall PLM phosphorylation stimulates NKA, while 
unphosphorylated PLM inhibits NKA activity [44,32] explaining the physiological 
role of PLM mentioned above.  
The regulation of PLM by phosphatases has been investigated to a much lesser extent 
than kinases, but recently it was shown that the Ser/Thr phosphatase 1 (PP-1) acts on 
Ser68 [45], but not on Thr69 under physiological conditions as the reported EC50 of 
2.7 μM for Thr69 was too high. Ser63 is dephosphorylated by Ser/Thr protein 
phosphatase 2A (PP-2A) [45], which was shown to be associated with the NKA 
complex [46]. As outlined above the PLM Ser63 dephosphorylation occurs most 
likely, when PLM is associated with NKA, but not in the PLM tetramer complex [23]. 
Taken together PLM phosphorylation exerts a protective effect on the heart muscle 
[47]. In the absence of PLM an increased heart rate and β-adrenergic stimulation 
would lead to a higher intracellular sodium concentration and a larger calcium 
content of the sarcoplasmic reticulum leading to more arrhythmias. NKA activation 
via phosphorylation of PLM prevents this.  
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4.2 Phospholemman palmitoylation 
As outlined in section two, PLM is palmitoylated at Cys40 and Cys42 [12]. The effect 
of palmitoylation is an increase of the half-life of PLM and a decrease of NKA 
activity. Furthermore, PLM phosphorylation at Ser68 increased its palmitoylation 
[12], which is surprising as phosphorylation and palmitoylation events are causing 
opposite effects. At this point the physiological significance of PLM palmitoylation 
has not been established. The enzymes responsible for palmitoylation of proteins are 
palmitoyl-S-transferase enzymes (known as DHHC proteins) and depalmitoylation is 
catalysed by thioesterase enzymes.  It was shown in human fibroblast-derived 
cardiomyocytes that overexpression of DHCC5 decreased NKA pump currents by 
55%, while siRNA knockdown of DHCC5 increased NKA pump currents by 38% 
[48]. Thus, DHCC5 contributes to palmitoylation of PLM leading to a subsequent 
decrease in NKA activity. In the same study it was postulated that the damage 
caused by reoxygenation of cardiac tissue after an ischemic event may be related to 
PLM palmitoylation. Upon reperfusion massive endocytosis of cardiac cell 
membrane including the NKA/PLM complex occurs that limits the recovery after an 
ischemic event.  Several observations linked PLM palmitoylation to this event, 
namely internalised PLM was palmitoylated to a higher level than cell-surface bound 
PLM and the extent of massive endocytosis was reduced in hearts lacking PLM or 
DHHC5. Thus reperfusion damage may be reduced by inhibition of palmitoylation 
[48]. The normal physiological function of PLM palmitoylation may be to regulate 
NKA under conditions of metabolic stress or to contribute to NKA/PLM turnover.  
 
4.3 Phospholemman glutathionylation 
The sensitivity of NKA to oxidative stress and to the cellular sulfhydryl redox status 
is already known since a long time [49,50] and linked to glutathionylation of the α 
[51] and β1 subunit [52], which both have inhibitory effects. PLM has been shown to 
reverse glutathionylation of the β1 subunit by becoming itself glutathionylated at 
Cys42, thus exerting an activating effect on NKA [13]. However, the physiological 
role of PLM glutathionylation is complicated, as it is linked with phosphorylation by 
PKA and palmitoylation that also occurs at Cys42. Palmitoylation of PLM, which has 
an inhibitory effect, is promoted by PKA phosphorylation at Ser68 [12], and to 
further complicate matters, oxidative stress can activate PKA [53]. Possibly 
electrophysiological modelling of cardiomyocyte activity taking explicit account of 
PLM could explain some of the complexities. Models of heart failure that highlight 
the importance of sodium currents and NKA activity have been recently presented 
[54], albeit modulation of NKA by PLM was not included. 
 
5 Conclusions 
PLM has emerged as an important modulator of NKA in particular under conditions 
of stress, such as increased heart rate or metabolic stress. A number of 
posttranslational modifications of PLM have been characterised and their 
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physiological consequences have been described. Further research is needed to 
understand the interplay between different posttranslational modifications and how 
they relate to overall cardiac physiology. Additionally, PLM regulation may occur at 
the level of gene expression, involving transcription, processing of mRNA, regulating 
the stability of mRNA and the rate of transcription. Gene regulation with regards to 
PLM is largely unexplored, but the exciting possibility of potassium ion-stabilised 
higher-order G-quadruplex structures of PLM pre-mRNA warrants further 
investigations. Progress has been made in the area of structural biology with the 
determination of high-resolution human homologue NKA/PLM structures, the 
structure of a PLM monomer and a tetramer complex. These structures can be used 
for comparative modelling of the human NKA/PLM complex as it was attempted for 
this review. However, experimentally determined protein structures and 
comparative models provide only a static picture, while the NKA-PLM interactions 
modulated by posttranslational modifications are surely dynamic. Most experimental 
methods investigating this dynamic interaction will be confounded by the 
heterogeneity of PLM posttranslational modifications in cardiomyocytes, thus single-
molecule based experimental methods together with complementary in silico 
simulation methods may be required to resolve this heterogeneity.  
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Table 1: Fxyd1 transcription factors detected in the ENCODE project based on ChIP-
Seq (minimum false discovery rate  = 0.05). A regions from 2500 bases upstream to 
500 bases downstream of the transcription start site was included. 
Transcription factor1 Function2 
BHLHE40 
CEBPB 
CMYC 
EGR1 
FOXA1 
 
 
GABP 
 
HNF4A 
HNF4G 
 
MAX 
 
MBD4 
MXI1 
 
P300 
 
 
POL2 
RXRA 
 
SP1 
 
TAF 
USF1 
 ZBTB7A 
Circadian control and cell differentiation. 
Transcriptional activator involved in immune and inflammatory responses. 
A proto-oncogene involved in cell division (negative regulation), apoptosis. 
Transcription activator of genes required for mitogenesis and differentiation. 
Embryonic development, establishment of tissue-specific gene expression, 
modulates transcriptional activity of nuclear hormone receptors, cell-cycle 
regulation, regulation of apoptosis, glucose homeostasis. 
Transcription activator, necessary for the expression of the adenovirus E4 
gene. 
Required for the transcription of alpha 1-antitrypsin, apolipoprotein CIII, 
transthyretin genes and HNF1-alpha, may be essential for development of 
the liver, kidney and intestine. 
Acts in complex with CMYC as repressor and in complex with MAD as 
activator. 
DNA N-glycosylase involved in DNA repair. 
Competes with CMYC for binding to MAX, thus antagonises CMYC 
function. 
Histone acetyltransferase P300, regulates transcription via chromatin 
remodelling, promotes cardiac myocyte enlargement, participates in 
circadian rythms. 
Subunit of RNA polymerase II, that synthesises mRNA precursors 
Retinoic acid receptor, regulates gene expression in complex with other 
nuclear receptors, regulates various biological processes 
Regulates expression of a large number of genes involved in cell growth, 
apoptosis, differentiation and immune response. 
General transcription factor required for transcription of genes 
Upstream stimulatory factor one, binds to the promotor of a variety of genes 
Transcription repressor,  possibly involved in the development of B-cells 
among other roles. 
1) Factors in bold are supported by the strongest level of evidence. 
2) Function obtained from UniprotKB [14]  
 15 
 
Figures: 
Figure 1: Multiple sequence alignment of FXYD1 orthologues. The alignment is 
coloured according to alignment quality (= conservation) with a red (low 
conservation) to blue (high conservation) gradient. Important functional sites of the 
human sequence discussed in the text are indicated. The figure was prepared with 
JalView [55]. 
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Figure 2: A) The structure of the PLM transmembrane domain tetramer showing the 
protein solvent-accessible surface. Residues in dark shade have been used to derive 
orientational constraints with site-specific infrared dichroim. B) A putative model of 
the PLM tetramer – NKA interaction utilising the tetramer as a storage form of PLM. 
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Figure 3: A protein surface model of NKA with PLM shown as ribbons colour coded 
by conservation calculated from the alignment shown in figure 1. Protein structure 
displays were made with Rasmol [56]. 
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Figure 4: A) A backbone ribbon display of the NKA/PLM complex based on 
comparative modelling with Modeller 9v6 [57] as explained in the text. B) Details of 
the interaction of PLM (blue) with NKA α1 (green tint) and β1 (blue tint) subunits. 
The amino acid residues from NKA interacting with PLM are shown in spacefill 
representation, while PLM residues are shown as sticks. C) Structural details of the 
C-terminal phosphorylation and palmitoylation/glutathionylation sites. 
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Figure 5: Detail of the interaction between PLM-Phe28 and NKA-α1-Glu960 shown 
to be important in FRET experiments. 
 
 
Figure 6: Cartoon of G-quadruplex formation in FXYD1 pre-mRNA between exon 6 
and exon 7 that may affect expression of the PLM protein product. 
 
